China Biotech

Business

From Brink to Black Friday Boom: Inside Jumia's African E-Commerce Turnaround

Once left for dead after a 95% stock collapse, Jumia Technologies AG is staging a remarkable comeback. A locally-focused strategy, a vast pickup station network, and a blockbuster Black Friday in Lagos signal the African e-commerce pioneer may finally be on a path to sustainable growth, even as it faces competition from global giants.

Feb 3, 2026

Business

ACADIA Pharmaceuticals: A Deep Value Play or a Value Trap?

After a significant rebound, ACADIA Pharmaceuticals (ACAD) shares present a conundrum for investors. While a discounted cash flow model suggests deep undervaluation, the stock's volatile history and mixed performance metrics demand a closer look at the underlying narrative.

Feb 3, 2026

Business

Gold Rebounds Sharply After Historic Plunge, Chinese Buyers Step In

Gold prices staged a significant recovery on Tuesday, regaining some ground after a historic two-day sell-off. The focus now shifts to Chinese retail investors, whose appetite for bargain-hunting ahead of the Lunar New Year could be pivotal for the market's near-term direction.

Feb 3, 2026

Business

Bio-Techne's Synthetic Hydrogel Launch Sparks Investor Interest Amid Mixed Long-Term Performance

Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.

Feb 3, 2026

Business

NIO's Multi-Brand Push and Record Deliveries Fuel Optimism for Path to Profitability

Chinese EV maker NIO Inc. is hitting new operational highs, reporting record quarterly deliveries and improving margins as its multi-brand strategy gains traction. With a strengthened balance sheet and a global expansion underway, analysts debate whether the company is nearing a crucial inflection point.

Feb 3, 2026

Business

Personalis' NeXT Personal Test: A Potential Game-Changer in Early Cancer Recurrence Detection

Personalis, Inc. (NASDAQ: PSNL) is attracting investor attention with its ultra-sensitive NeXT Personal blood test, capable of detecting cancer recurrence far earlier than standard methods. With a key distribution deal and anticipated Medicare reimbursement, the company could be on the cusp of a significant inflection point.

Feb 3, 2026

Business

Oatly's Turnaround Gains Momentum: First Operating Profit in a Decee Sparks Bullish Sentiment

After years of struggle, Oatly Group AB (OTLY) is showing concrete signs of a sustainable turnaround, posting its first quarterly operating profit in ten years. Strategic moves, including debt restructuring and a key investor stake, are fueling optimism for the oatmilk pioneer's path to profitability.

Feb 3, 2026

Business

Niagen Bioscience: The Science-Backed Longevity Play Building a Regulatory Fortress

With its patented, FDA-recognized compound Niagen®, Niagen Bioscience (NAGE) has carved out a unique and defensible position at the intersection of nutraceuticals and pharmaceuticals. As the cellular health market expands, the company's dual-channel strategy and deep scientific validation present a compelling growth narrative for investors.

Feb 3, 2026

Business

Stellantis Shares in the Doldrums: Is the Auto Giant a Bargain After a Steep Slide?

Stellantis shares have shed over a quarter of their value in the past year, trading at a steep discount to industry peers. A deep dive into valuation metrics suggests the market may be overlooking the carmaker's fundamentals, presenting a potential opportunity for value-focused investors.

Feb 3, 2026

Business

Vaxcyte Secures Major Funding, Advances Key Vaccine to Phase 3 Trials

Vaxcyte (PCVX) bolsters its financial position with a successful public offering, channeling fresh capital into pivotal late-stage trials for its broad-spectrum pneumococcal vaccine candidate, VAX-31, in both adults and infants.

Feb 3, 2026

Business

Pfizer Bolsters Vaccine Pipeline with Novavax Adjuvant Deal, Eyes Post-COVID Growth

Pfizer has secured global rights to Novavax's Matrix-M adjuvant technology, aiming to develop new vaccines for infectious diseases as it seeks to diversify its portfolio beyond pandemic-related sales.

Feb 3, 2026

Business

Hongkong Land Holdings: Is the Property Giant Trading at a Fair Value?

A discounted cash flow analysis suggests Hongkong Land Holdings (SGX:H78) is trading close to its intrinsic value. We delve into the model's assumptions and what it means for investors in the current market climate.

Feb 3, 2026

Business

Insulet's Omnipod Momentum: Can the Insulin Pump Leader Sustain Its Growth Trajectory?

Insulet Corporation (NASDAQ: PODD), the maker of the tubeless Omnipod insulin delivery system, is drawing investor attention with a potent mix of surging cash flow, market expansion, and a recurring revenue model. As the company capitalizes on recent regulatory wins and international growth, we examine the bull case and the risks ahead.

Feb 3, 2026

Business

KLA Corporation: The Unseen Engine Powering the AI Chip Boom

As semiconductor manufacturing grows more complex, KLA's process control systems are becoming indispensable. With a dominant market position and resilient financials, the company is positioned to capitalize on long-term industry trends, though its premium valuation invites scrutiny.

Feb 3, 2026

Business

AXT, Inc.: The Unseen Semiconductor Play Powering the AI Infrastructure Boom

As data centers scramble to upgrade for the AI era, a critical bottleneck has emerged in optical communications. AXT, Inc., a specialist in compound semiconductor substrates, finds itself at the center of this shift, leveraging a unique supply chain advantage to meet explosive demand for indium phosphide.

Feb 3, 2026

US

EU's Revised 2035 Climate Rules Could See Electric Vehicle Sales Drop to 50%, Advocacy Group Warns

Brussels-based clean transport group Transport & Environment warns that the European Commission's proposed easing of 2035 emissions targets may allow combustion-engine cars to make up half of new sales, marking a significant retreat from earlier climate ambitions.

Feb 3, 2026

Business

Apple Shatters Records with $143B Quarter, Yet AI Ambitions and Memory Costs Loom

Apple's historic Q1 earnings, fueled by unprecedented iPhone demand, sent its stock on a wild ride. While the results dazzled Wall Street, muted guidance on memory cost pressures and questions about its AI roadmap tempered the celebration.

Feb 3, 2026

Business

Apple's Record Quarter Fuels Investor Debate: Is the AI and iPhone Momentum Already Priced In?

Apple's stellar earnings, driven by robust iPhone demand and growth in key markets, have reignited investor optimism. Yet, a significant valuation gap persists, sparking debate on whether the stock's AI-driven future justifies its current premium.

Feb 3, 2026

Business

Senseonics Sees Analyst Target Cut Amid Post-Split Scrutiny

Analysts have slashed Senseonics Holdings' 12-month price target by 40%, signaling heightened caution on the medical device maker's execution path following its stock split, despite maintaining a bullish long-term revenue model.

Feb 3, 2026

Business

InSilico Medicine's 60% Surge: AI Hype or Justified Valuation?

InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.

Feb 3, 2026